- Home
- NEWS
- REGIONAL
- THIS WEEK'S PAPER
- BLOGS
- Multimedia
- OPINION
- A&E
- LISTS
- PEOPLE
- EVENTS
- Classifieds
- Subscribe
Pharmaceutical
Lilly Alzheimer's drug prospect only the latest to fail
August 18, 2010
Bloomberg NewsA dozen potential products designed to slow or stop clumps of protein from forming in the brain, a condition linked to the
disease since 1906, have failed in mid- to late-stage testing since 2003.
MoreLilly's Cymbalta helps chronic pain in U.S. review
August 17, 2010
Bloomberg NewsApproval for the millions of Americans with chronic back or knee pain may add more than $500 million, or 16 percent, to Cymbalta's
annual sales.
MoreLilly halts development of Alzheimer's drug
August 17, 2010
IBJ Staff and Associated PressStudies showed that the treatment did not slow the disease's progression. It's just the latest setback for the pharmaceutical
giant, which lost a patent lawsuit over a major drug last week and faces an unprecedented number of patent expirations through
2014.
MoreLilly braces for plunge in profits
August 14, 2010
J.K. WallIndianapolis-based drugmaker Eli Lilly and Co. faces such an unprecedented string of patent expirations and an unheard-of
loss of revenue that it's hard to picture what the company will look like in five years.
MoreEli Lilly loses patent lawsuit for Strattera
August 13, 2010
IBJ Staff and Associated PressEli Lilly and Co. on Thursday lowered its revenue outlook for the year after it lost a patent lawsuit over its attention
deficit hyperactivity drug Strattera. The patent had been set to expire in May 2017. Lilly plans to appeal.
MoreLilly among bidders for Denmark company, source says
July 30, 2010
Bloomberg NewsCopenhagen-based health-care company Ascendis Pharma A/S received offers of about $400 million, an unidentified source said.
Ascendis may choose a final bidder by early September.
MoreLilly loses appeal over patent for cancer drug Gemzar
July 28, 2010
IBJ Staff and Bloomberg NewsA U.S. appeals court Wednesday said a lower court was correct to invalidate a patent on the medicine that expires in 2013.
Gemzar generated $1.36 billion in global sales in 2009.
MoreNew rules raise stakes for Lilly drug
July 21, 2010
J.K. WallDrugmakers testing experimental Alzheimer’s medicines—including Eli Lilly and Co.—got good news last week
when the National Institute on Aging and the Alzheimer’s Association proposed new guidelines to make earlier diagnoses
of the disease.
MoreLilly reveals plans to cut 340 IT jobs
July 15, 2010
J.K. WallThe Indianapolis-based drugmaker eliminated 140 information technology jobs in June through retirements, resignations and
some cuts. Another 115
cuts will be made this month, and the remainder by the end of the year.
MoreLilly's Alzheimer's gamble takes aim at $10 billion in patent losses
July 13, 2010
Bloomberg NewsBoth of Lilly's late-stage treatments are designed to reduce plaque in the brain called beta amyloid, thought by researchers
to be a main contributor to Alzheimer's. A drug that stops or reduces memory loss caused by Alzheimer's may be worth more
than $5 billion
a year, an analyst says, helping Lilly overcome the coming patent losses on several important pharmaceuticals.
MoreLilly to cut 170 manufacturing jobs by year's end
July 12, 2010
J.K. WallEli Lilly and Co. will cut 170 jobs—mostly in Indianapolis—from its manufacturing and quality division by the
end of the year as it continues its efforts to slim down before losing revenue from patent expirations on its bestselling
drugs.
MoreContract pharmaceutical research firm expands to New Jersey
July 10, 2010
J.K. WallConcentrics grows in spite of recession as drug companies look for help to handle patent expirations
MoreLilly's Lechleiter: No change in plans
July 7, 2010
J.K. WallThe global financial press keeps asking John Lechleiter for his end-game strategy to survive Eli Lilly and Co.'s nightmarish
patent challenges. And, like a broken record, the Lilly CEO keeps giving the same answer: pipeline, pipeline, pipeline—no
mega-merger.
MoreMen on Viagra, Cialis show triple rate of sex diseases in study
July 6, 2010
IBJ Staff and Bloomberg NewsThe findings suggest that users of drugs to treat erectile dysfunction, including Eli Lilly's Cialis, may be more likely to
engage in unsafe sex than nonusers.
MoreLilly acquires biotech company with pancreatic drug
July 2, 2010
J.K. WallMassachusetts-based Alnara Pharmaceuticals Inc., which has attracted $55 million in venture capital in the past two years,
recently submitted its drug to the FDA for market approval.
MoreGrassley asks Lilly, peers about whistleblower treatment
July 1, 2010
Bloomberg NewsU.S. Senator Charles Grassley asked 16 drugmakers, including Eli Lilly & Co., Pfizer Inc. and AstraZeneca Plc, to reveal
how they treat whistleblowers who file complaints under the False Claims Act.
MoreMarcadia enlists Lilly to help develop new diabetes drug
June 28, 2010
J.K. WallThe two companies will jointly develop a short-acting glucagon drug, which they hope proves more convenient than Lilly’s
current Glucagon for patients with severe hypoglycemia.
MoreLilly, Amylin stock rises on drug postponement
June 18, 2010
IBJ Staff and Bloomberg NewsRoche Holding AG's decision to postpone its experimental diabetes drug is helping boost shares in Amylin Pharmaceuticals
Inc. and drug partner Eli Lilly and Co.
MoreResearch reforms will force Lilly, others to test how drugs stack up
June 12, 2010
J.K. WallThe federal government is currently doling out $1.1 billion in stimulus funds to pay for research that compares multiple medical
treatments against one another to determine which is most effective. Drug companies like Eli Lilly and Co. are wary that comparative-effectiveness
research could threaten their sales.
MoreArcadia sees smaller quarterly, fiscal-year losses
June 11, 2010
Scott OlsonDespite losses, company sees growth in its DailyMed pharmacy services, which packages the right dosages of prescriptions to
make it easier for patients to follow their regimens.
MoreErbitux fails to stop colon cancer before it spreads
June 6, 2010
Bloomberg NewsEli Lilly and Co. and Merck KGaA drug failed to slow tumors in a study designed to expand the medicine's use to patients whose
disease is in an earlier stage.
MoreGenetic testing could spur Erbitux drug sales
June 1, 2010
Bloomberg NewsThe drugmakers are counting on screening for the so-called K-ras gene to spur use of Erbitux in metastatic colorectal cancer.
MoreCancer researcher battling Semafore in court
May 29, 2010
Chris O'MalleyFormer collaborator alleges firm breached its agreement with him and refused to pay royalty income.
MoreLilly grows Alimta's sales by shrinking market
May 29, 2010
J.K. WallIn 2008, Eli Lilly and Co. asked drug regulators to change the label on Alimta so Lilly could no longer promote it as a treatment
for all patients suffering from non-small-cell lung cancer, but for only about 70 percent of the patients. Since then, sales
of the drug have accelerated, growing a whopping 48 percent last year.
MoreBiopharma fueling boom in refrigerated warehousing
May 29, 2010
Chris O'MalleyIn the past few years, a handful of cold storage facilities have sprouted locally by playing to Indianapolis' strengths
in warehousing and life sciences.
More
Sponsored by
ADVERTISEMENT
on Facebook & Twitter
on Facebook & Twitter
 Follow IBJ's Tweets on these topics: |
||
| @IBJNews | @Propertylines | @IBJTheScore |
| @IBJArts | @IBJHealthcare | @IBJDining |
| @IBJLists | @IBJSmallbiz | |
ADVERTISEMENT
Back to TopCopyright © All Rights Reserved. Privacy Policy | Terms of Use.
Design, CMS, Hosting & Web Development :: ePublishing.
Additional Hosting & Delivery by
See, I told u Indyman and Dipsicle....this 8 days is overkill. It's barely worth a weekend....great job Tony George! Your dream has been fulfilled....he fans want the I r l back. Thats how good it was.....and that sucked.
I have been in training for a short time now but right off I can see that safety and quality are the number one issues, my experience as of late has been a positive one, the employees along with Jeff the plant manager and the operation supervisor as well as the engineers are a highly motivated group of people, what an asset for the area to have and for company's in need of a quality metal products.
Pimlico
While I understand the severity of their actions as well as everyones eagerness to hold them responsible for thier lost funds, these gentlemen did know how to make money. Dispite thier poor decisions over the ownership of Fair they had made several wise investments which paid them greatly. This proves they do have the potential to rebuild so they can repay. I do not feel they should live the life of luxuary but given an opportunity could they find ways of repaying the debts? They are doing nothing now but being a burden on tax payers. Just a thought!!!!!
You guys have some "interesting" comments to say the least. I hope you will call in and share those opinions starting June 1. I'm looking forward to having you on the air.